Alvotech Starts Confirmatory Study for Biosimilar Candidate to Entyvio
Hutchmed's Partner Takeda Pharmaceutical Gets Go-Ahead to Produce, Market Colorectal Cancer Drug in Japan
Hutchmed's Partner Wins Japan Approval for Colorectal Cancer Treatment
Takeda Pharmaceutical Says Colorectal Cancer Drug Received Marketing Approval in Japan
Takeda's FRUZAQLA Capsules Approved in Japan for Advanced Colorectal Cancer Treatment
Express News | Takeda Pharmaceutical: Japan has approved FRUZAQLA (FRUQUINTINIB) for the treatment of unresectable advanced or recurrent colorectal cancer.
Express News | Takeda Receives Approval for Fruzaqla (Fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○List of stocks for buying conversion in the market Code Stock Name Closing Price SAR Tokyo Stock Exchange main board <1377> Sakata no Tane 3420 3325 <1379> Hokuto 1819 1778 <1417> Miraitowa 2064 1988 <1419> Tamahome 4020 3765 <1663> K&O Energy 3
Sanofi Sarclisa Combo Gains Approval as First-line Multiple Myeloma Treatment
ADR Japanese stock rankings - General buying predominance such as Advantest, Chicago is 37,530 yen, which is 640 yen higher than Osaka.
Japanese stocks of ADR (American Depositary Receipt) such as Advantest <6857>, Disco <6146>, Tokyo Electron <8035>, Japan Post <6178>, Mitsubishi UFJ Financial Group <8306>, Mizuho Financial Group <8411>, Renesas <6723>, Terumo <4543>, Marubeni <8002>, etc. rose compared to the Tokyo Stock Exchange at an exchange rate of 1 dollar to 142.62 yen, and overall buying pressure was dominant. The settlement price of the Chicago Nikkei 225 futures was 37,530 yen, 640 yen higher than the Osaka day session. The US stock market is
Wave Life Sciences Gains as B. Riley Issues Buy on RNS Editing Tech
Takeda To Present Additional Clinical Trial Study Data Highlighting The Impact Of Orexin Agonist TAK-861 On The Burden Of Narcolepsy At Sleep Europe 2024
Express News | Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist Tak-861 on the Burden of Narcolepsy at Sleep Europe 2024
Fanpep Research Memo (9): In addition to expanding the pipeline of antibody-inducing peptides, the subsidiary is also developing non-pharmaceutical businesses.
■ Fan Pep <4881> will continue to expand its development pipeline focusing on diseases with high development significance among a wide range of chronic diseases, mainly in the "inflammation area" where antibody pharmaceuticals have already been launched, leveraging its unique technology of antibody-conjugated peptides. Since the target protein is the same as the antibody pharmaceuticals that are already on the market, the time needed to identify lead compounds can be significantly shortened, and safety and effectiveness have already been confirmed with antibody pharmaceuticals.
Takeda Commits Over $32M in Five New CSR Partnerships
Axcelead DDP and Lilly Enter Into Research and Collaboration Agreement
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Today's flows: 09/17 SMC saw an inflow of JPY¥ 1.38 billion, Tokyo Electron saw an outflow of JPY¥ 6.74 billion
On September 17th, the TSE Main Market saw an inflow of JPY¥ 649.31 billion and an outflow of JPY¥ 690.51 billion.$SMC(6273.JP)$, $Mitsubishi Heavy Industries(7011.JP)$ and $Takeda Pharmaceutical(4502
Nikkei Average Contribution Ranking (Before Closing) - Nikkei Average plunged significantly, with Toshiba Electronic pushing down by about 144 yen in one stock.
As of the close on the 17th, the number of rising stocks in the Nikkei Average constituent stocks was 43, the number of declining stocks was 182, and the number of unchanged stocks was 0. The Nikkei Average continued to decline. Compared to the previous trading day, it finished the morning session at 35,828.54 yen (volume estimated at 900,100,000 shares) with a decrease of 753.22 yen (-2.06%). The US stock market on the 16th was mixed. The Dow Average closed at 41,622.08 yen, up 228.30 yen (+0.55%), and the Nasdaq was down 91.85 points (-0.52%) at 17.
Vatroslav Mateljic Appointed General Manager Of Takeda Canada